The company’s exhibitions will be focused in the areas of its pipeline, proprietary capsid engineering, and manufacturing. Thousand Oaks, Calif.-based Capsida Biotherapeutics (Capsida) has announced ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that ...
This year’s Research and Creativity Symposium set a record, with 109 students participating. The symposium is an event on ...
LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros B.V., a clinical-stage biotechnology company focused on rare diseases and lysosomal storage disorders, today announced that advancements with its lead ...
4 IDEAYA/GSK presentations of IDE275 (GSK959) and 4 additional presentations across IDE397/MAT2A, IDE161/PARG, PRMT5, and KAT6/7 programs at AACR 2025 IDE275 (GSK959) has demonstrated a potential best ...
CHICAGO and FORT WORTH, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate” or the "Company”), a clinical-stage biopharmaceutical company focused on ...
Perosphere (Perosphere Technologies Inc.), a private medical technologies company focused on developing next-generation coagulation diagnostics, today announced its participation on the agenda of the ...
Upon abstract acceptance, all posters must be uploaded and recorded on VoiceThread by January 26, 2026 at 5 p.m. All posters that are narrated on VoiceThread by the deadline will be officially listed ...
In addition, Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium, discussing nizubaglustat’s profile and plans for global Phase 3 studies Six presentations will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results